Gao WeiLi, Liu LiWei, Ye GuoChao, Lu Wei, Teng LiSong
Department of General Surgery, Huzhou Central Hospital, Huzhou Department of Surgical Oncology, The First Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Surg Laparosc Endosc Percutan Tech. 2015 Feb;25(1):19-22. doi: 10.1097/SLE.0b013e3182a50f1f.
The aim of this study was to analyze the clinicopathologic characteristics and postoperative outcomes and to evaluate the feasibility of the bilateral areolar approach (BAA) endoscopic thyroidectomy for low-risk papillary thyroid carcinoma (PTC).
From January 2012 to February 2013, 137 low-risk PTC patients underwent BAA endoscopic thyroidectomy. Their clinicopathologic characteristics and postoperative outcomes (postoperative cosmetic satisfaction, type of thyroidectomy, number of lymph nodes, postoperative complications, and recurrence of disease) were analyzed.
The 137 patients comprised 135 female and 2 male individuals. The average age of patients was 32.02±8.32 years. The mean tumor size was 0.82±0.41 cm. The ratio of minimal extrathyroidal extension patients was 1:19.6. According to the American Joint Committee on Cancer tumor stage, 132 cases were stage I and 5 cases were stage III. The mean follow-up period was 7.80±3.86 months (range, 3 to 15 mo, and median, 7 mo). At 3 months, postoperatively, patients were very satisfied with the cosmetic result as evaluated by a 10-point visual analogue scale (9.14±1.17). After surgery, the mean number of lymph nodes was 5.70±2.92, whereas the mean number of lymph node metastases was 1.06±1.96. Regarding the major postoperative complications, the rates of transient recurrent laryngeal nerve palsy and transient hypoparathyroidism were 4.4% and 27.7%, respectively. None of the patients experienced a thyroid cancer-related death or recurrence.
BAA is feasible and safe for the treatment of low-risk PTC patients, with favorable cosmesis. Thus, it is an alternative therapeutic treatment for selected patients with low-risk PTC. However, oncologic safety of BAA thyroidectomy for PTC patients needs to be verified by a large comparative series and long-term follow-up.
本研究旨在分析低危乳头状甲状腺癌(PTC)患者的临床病理特征及术后结局,并评估乳晕入路(BAA)内镜甲状腺切除术治疗低危PTC的可行性。
2012年1月至2013年2月,137例低危PTC患者接受了BAA内镜甲状腺切除术。分析其临床病理特征及术后结局(术后美容满意度、甲状腺切除术类型、淋巴结数量、术后并发症及疾病复发情况)。
137例患者中,女性135例,男性2例。患者平均年龄为32.02±8.32岁。肿瘤平均大小为0.82±0.41 cm。甲状腺外微小侵犯患者比例为1:19.6。根据美国癌症联合委员会肿瘤分期,132例为I期,5例为III期。平均随访期为7.80±3.86个月(范围3至15个月,中位数7个月)。术后3个月,患者对美容效果非常满意,采用10分视觉模拟评分法评估得分为9.14±1.17。术后平均淋巴结数量为5.70±2.92,平均淋巴结转移数量为1.06±1.96。关于主要术后并发症,暂时性喉返神经麻痹和暂时性甲状旁腺功能减退的发生率分别为4.4%和27.7%。所有患者均未发生甲状腺癌相关死亡或复发。
BAA治疗低危PTC患者可行且安全,美容效果良好。因此,对于部分低危PTC患者,它是一种可供选择的治疗方法。然而,BAA甲状腺切除术治疗PTC患者的肿瘤学安全性需要通过大型对比研究系列和长期随访来验证。